Search research articles
Contact Us
Filters
Showing results (521-530 of 551) with videos related to
Page
of 56
Sort By:
Medrxiv : the Preprint Server for Health Sciences
|
August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
Peter B Gilbert, David C Montefiori, Adrian McDermott, et al.
Mbio
|
September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trials
Raabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Nature Communications
|
September 11, 2024
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial
Bo Zhang, Youyi Fong, Jonathan Fintzi, et al.
Plos Pathogens
|
June 29, 2023
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
Nonhlanhla N Mkhize, Anna E J Yssel, Haajira Kaldine, et al.
Nature Medicine
|
August 22, 2022
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
Peter B Gilbert, Yunda Huang, Allan C deCamp, et al.
The New England Journal of Medicine
|
September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Ann R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccine
Youyi Fong, Yunda Huang, Ying Huang, et al.
Ebiomedicine
|
June 10, 2023
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Kelly E Seaton, Yunda Huang, Shelly Karuna, et al.
The New England Journal of Medicine
|
March 17, 2021
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Lawrence Corey, Peter B Gilbert, Michal Juraska, et al.
The Lancet. HIV
|
May 11, 2026
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial
Sharana Mahomed, Carmen A Paez, Yunda Huang, et al.
Page
of 56
Search research articles
Search
Showing results (521-530 of 551) with videos related to
Sort By:
Page
of 56
Medrxiv : the Preprint Server for Health Sciences
|
August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
Peter B Gilbert, David C Montefiori, Adrian McDermott, et al.
Mbio
|
September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trials
Raabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Nature Communications
|
September 11, 2024
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial
Bo Zhang, Youyi Fong, Jonathan Fintzi, et al.
Plos Pathogens
|
June 29, 2023
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
Nonhlanhla N Mkhize, Anna E J Yssel, Haajira Kaldine, et al.
Nature Medicine
|
August 22, 2022
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
Peter B Gilbert, Yunda Huang, Allan C deCamp, et al.
The New England Journal of Medicine
|
September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Ann R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccine
Youyi Fong, Yunda Huang, Ying Huang, et al.
Ebiomedicine
|
June 10, 2023
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Kelly E Seaton, Yunda Huang, Shelly Karuna, et al.
The New England Journal of Medicine
|
March 17, 2021
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Lawrence Corey, Peter B Gilbert, Michal Juraska, et al.
The Lancet. HIV
|
May 11, 2026
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial
Sharana Mahomed, Carmen A Paez, Yunda Huang, et al.
Page
of 56